Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04485013 · ClinicalTrials.gov registry record · Phase 1
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
A Phase 1 study of Cancer, sponsored by Tizona Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT04485013: Recruiting Phase 1 study of Cancer, sponsored by Tizona Therapeutics.
NCT04485013 is a Phase 1 study of Cancer that is actively recruiting participants, run by Tizona Therapeutics. The registered enrollment target is 240 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04485013, a Phase 1 study of Cancer, is actively recruiting participants, sponsored by Tizona Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients.
Conditions Studied
Interventions
- DRUG pembrolizumab
- DRUG cetuximab
- DRUG FOLFIRI
- DRUG TTX-080
Study Locations (20)
Florida
- Florida Cancer Specialists - Daytona Beach
- Florida Cancer Specialists - Fleming Island
- Ocala Oncology Center - Ocala
- AdventHealth Research Institute - Orlando
California
- University of Southern California - Los Angeles
- Hoag Memorial Hospital - Newport Beach
Illinois
- Illinois Cancer Specialists - Arlington Heights
- University of Illinois - Chicago
Maryland
- American Oncology Partners, P.A. - The Center for Cancer & Blood Disorders - Bethesda
- Maryland Oncology Hematology - Silver Spring
Arizona
- Arizona Oncology Associates - Tucson
Colorado
- Rocky Mountain Cancer Centers - Denver
Connecticut
- Yale Cancer Center - New Haven
Delaware
- Christiana Care Helen F. Graham Cancer Center - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2020-07-14 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 1 |
What NCT04485013 shows while recruiting
NCT04485013 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 4 interventions - of which pembrolizumab is the first listed.
NCT04485013 names 20 study sites across 14 states, led by Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT04485013 about?
NCT04485013 is a clinical study titled "TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers". TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI pl...
What is the current status of trial NCT04485013?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2020-07-14. Estimated completion is 2027-06-01.
What conditions does trial NCT04485013 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT04485013?
The interventions under investigation include: pembrolizumab (DRUG), cetuximab (DRUG), FOLFIRI (DRUG), TTX-080 (DRUG).
Who is sponsoring clinical trial NCT04485013?
This trial is sponsored by Tizona Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04485013 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04485013's enrollment target sits among peer trials
240 211th of 615 higher than 400 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI